| | Business Summary | | Biopure
Corporation
develops,
manufactures
and
markets
Oxygen
Therapeutics.
Its
products
are
Hemopure,
for
human
use,
and
Oxyglobin,
for
veterinary
use.
Biopure
is
developing
Hemopure
as
an
alternative
to
red
blood
cell
transfusions
as
well
as
for
use
in
the
treatment
of
other
critical
care
conditions.
A
Hemopure
pivotal
Phase
III
clinical
trial
in
the
United
States
has
completed
patient
enrollment
and
follow-up.
The
data
from
that
trial
are
being
monitored
and
analyzed.
In
1998,
following
FDA
approval,
Biopure
began
selling
Oxyglobin
in
the
United
States.
In
December
1999,
Biopure
received
approval
to
sell
Oxyglobin
in
the
countries
of
the
European
Union,
and
it
intends
to
begin
selling
the
product
in
2001. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Biopure
Corporation
develops,
manufactures
and
markets
oxygen
therapeutics,
for
both
human
and
veterinary
use,
designed
to
serve
as
an
alternative
to
red
blood
cell
transfusions
and
for
use
in
the
treatment
of
other
critical
care
conditions.
For
the
six
months
ended
4/30/01,
revenues
rose
20%
to
$1.6
million.
Net
loss
rose
27%
to
$28.1
million.
Revenues
reflect
higher
sales
of
Oxyglobin(R).
Loss
also
reflects
increased
non-cash
compenation
expense
for
stock
options. Recent Earnings Announcement
For
the
3
months
ended
07/31/2001,
revenues
were
946;
after
tax
earnings
were
-11,922. (Preliminary; reported in thousands of dollars.) | | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Carl Rausch, 52
Chairman
and CEO | $372K | Paul Looney, 61
Pres | 357K | David Judelson, 72
Vice
Chairman | -- | Francis Murphy, 62
CFO | -- | Jane Kober, 57
Sr.
VP, Gen. Counsel and Sec. | 322K | | Dollar amounts are as of 31-Oct-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/b/bpur.gif)